nodes	percent_of_prediction	percent_of_DWPC	metapath
Clodronate—SLC25A6—skin of body—acquired immunodeficiency syndrome	0.0124	0.0453	CbGeAlD
Clodronate—SLC25A4—retina—acquired immunodeficiency syndrome	0.0116	0.0421	CbGeAlD
Clodronate—SLC25A5—Host Interactions of HIV factors—APOBEC3G—acquired immunodeficiency syndrome	0.0113	0.0699	CbGpPWpGaD
Clodronate—SLC25A5—skin of body—acquired immunodeficiency syndrome	0.0108	0.0394	CbGeAlD
Clodronate—SLC25A6—lymphoid tissue—acquired immunodeficiency syndrome	0.0101	0.0367	CbGeAlD
Clodronate—SLC25A6—digestive system—acquired immunodeficiency syndrome	0.00995	0.0362	CbGeAlD
Clodronate—SLC25A5—Host Interactions of HIV factors—CCNT1—acquired immunodeficiency syndrome	0.00961	0.0595	CbGpPWpGaD
Clodronate—SLC25A6—blood—acquired immunodeficiency syndrome	0.00948	0.0345	CbGeAlD
Clodronate—SLC25A6—Host Interactions of HIV factors—APOBEC3G—acquired immunodeficiency syndrome	0.00947	0.0586	CbGpPWpGaD
Clodronate—SLC25A6—bone marrow—acquired immunodeficiency syndrome	0.00917	0.0334	CbGeAlD
Clodronate—SLC25A6—spinal cord—acquired immunodeficiency syndrome	0.00913	0.0333	CbGeAlD
Clodronate—SLC25A5—lymphoid tissue—acquired immunodeficiency syndrome	0.00876	0.0319	CbGeAlD
Clodronate—SLC25A5—digestive system—acquired immunodeficiency syndrome	0.00866	0.0315	CbGeAlD
Clodronate—SLC25A6—lung—acquired immunodeficiency syndrome	0.00831	0.0303	CbGeAlD
Clodronate—SLC25A5—blood—acquired immunodeficiency syndrome	0.00825	0.03	CbGeAlD
Clodronate—SLC25A4—digestive system—acquired immunodeficiency syndrome	0.00811	0.0295	CbGeAlD
Clodronate—SLC25A6—Host Interactions of HIV factors—CCNT1—acquired immunodeficiency syndrome	0.00806	0.0498	CbGpPWpGaD
Clodronate—SLC25A5—bone marrow—acquired immunodeficiency syndrome	0.00798	0.0291	CbGeAlD
Clodronate—SLC25A5—spinal cord—acquired immunodeficiency syndrome	0.00795	0.0289	CbGeAlD
Clodronate—SLC25A6—nervous system—acquired immunodeficiency syndrome	0.0077	0.028	CbGeAlD
Clodronate—SLC25A5—vagina—acquired immunodeficiency syndrome	0.00764	0.0278	CbGeAlD
Clodronate—SLC25A4—spinal cord—acquired immunodeficiency syndrome	0.00745	0.0271	CbGeAlD
Clodronate—SLC25A6—central nervous system—acquired immunodeficiency syndrome	0.00741	0.027	CbGeAlD
Clodronate—SLC25A4—Host Interactions of HIV factors—APOBEC3G—acquired immunodeficiency syndrome	0.0074	0.0457	CbGpPWpGaD
Clodronate—SLC25A5—HIV Infection—APOBEC3G—acquired immunodeficiency syndrome	0.00735	0.0454	CbGpPWpGaD
Clodronate—SLC25A5—lung—acquired immunodeficiency syndrome	0.00723	0.0263	CbGeAlD
Clodronate—SLC25A4—vagina—acquired immunodeficiency syndrome	0.00716	0.0261	CbGeAlD
Clodronate—SLC25A4—lung—acquired immunodeficiency syndrome	0.00677	0.0247	CbGeAlD
Clodronate—SLC25A5—nervous system—acquired immunodeficiency syndrome	0.0067	0.0244	CbGeAlD
Clodronate—SLC25A5—central nervous system—acquired immunodeficiency syndrome	0.00645	0.0235	CbGeAlD
Clodronate—SLC25A4—Host Interactions of HIV factors—CCNT1—acquired immunodeficiency syndrome	0.00629	0.0389	CbGpPWpGaD
Clodronate—SLC25A4—nervous system—acquired immunodeficiency syndrome	0.00627	0.0228	CbGeAlD
Clodronate—SLC25A5—HIV Infection—CCNT1—acquired immunodeficiency syndrome	0.00625	0.0386	CbGpPWpGaD
Clodronate—SLC25A6—HIV Infection—APOBEC3G—acquired immunodeficiency syndrome	0.00616	0.0381	CbGpPWpGaD
Clodronate—SLC25A4—central nervous system—acquired immunodeficiency syndrome	0.00604	0.022	CbGeAlD
Clodronate—SLC25A6—brain—acquired immunodeficiency syndrome	0.00588	0.0214	CbGeAlD
Clodronate—SLC25A6—lymph node—acquired immunodeficiency syndrome	0.00568	0.0207	CbGeAlD
Clodronate—SLC25A6—HIV Infection—CCNT1—acquired immunodeficiency syndrome	0.00523	0.0324	CbGpPWpGaD
Clodronate—SLC25A5—brain—acquired immunodeficiency syndrome	0.00512	0.0186	CbGeAlD
Clodronate—SLC25A5—lymph node—acquired immunodeficiency syndrome	0.00494	0.018	CbGeAlD
Clodronate—SLC25A4—HIV Infection—APOBEC3G—acquired immunodeficiency syndrome	0.00481	0.0297	CbGpPWpGaD
Clodronate—SLC25A4—brain—acquired immunodeficiency syndrome	0.0048	0.0175	CbGeAlD
Clodronate—PTGS2—endothelium—acquired immunodeficiency syndrome	0.00477	0.0174	CbGeAlD
Clodronate—SLC25A4—lymph node—acquired immunodeficiency syndrome	0.00463	0.0169	CbGeAlD
Clodronate—SLC25A6—Metabolism of proteins—ENPEP—acquired immunodeficiency syndrome	0.00454	0.0281	CbGpPWpGaD
Clodronate—PTGS2—blood plasma—acquired immunodeficiency syndrome	0.00424	0.0154	CbGeAlD
Clodronate—SLC25A4—HIV Infection—CCNT1—acquired immunodeficiency syndrome	0.00409	0.0253	CbGpPWpGaD
Clodronate—SLC25A4—Metabolism of proteins—ENPEP—acquired immunodeficiency syndrome	0.00354	0.0219	CbGpPWpGaD
Clodronate—SLC25A5—HIV Infection—CXCR4—acquired immunodeficiency syndrome	0.00328	0.0203	CbGpPWpGaD
Clodronate—SLC25A6—HIV Infection—CXCR4—acquired immunodeficiency syndrome	0.00275	0.017	CbGpPWpGaD
Clodronate—SLC25A5—HIV Infection—CCR5—acquired immunodeficiency syndrome	0.00225	0.0139	CbGpPWpGaD
Clodronate—SLC25A5—Host Interactions of HIV factors—CD4—acquired immunodeficiency syndrome	0.00217	0.0134	CbGpPWpGaD
Clodronate—SLC25A4—HIV Infection—CXCR4—acquired immunodeficiency syndrome	0.00215	0.0133	CbGpPWpGaD
Clodronate—SLC25A4—SIDS Susceptibility Pathways—IL10—acquired immunodeficiency syndrome	0.00211	0.0131	CbGpPWpGaD
Clodronate—PTGS2—skin of body—acquired immunodeficiency syndrome	0.00204	0.00742	CbGeAlD
Clodronate—SLC25A5—Metabolism—TAT—acquired immunodeficiency syndrome	0.00189	0.0117	CbGpPWpGaD
Clodronate—SLC25A6—HIV Infection—CCR5—acquired immunodeficiency syndrome	0.00188	0.0117	CbGpPWpGaD
Clodronate—SLC25A6—Host Interactions of HIV factors—CD4—acquired immunodeficiency syndrome	0.00182	0.0113	CbGpPWpGaD
Clodronate—SLC25A5—Disease—APOBEC3G—acquired immunodeficiency syndrome	0.0018	0.0111	CbGpPWpGaD
Clodronate—PTGS2—lymphoid tissue—acquired immunodeficiency syndrome	0.00165	0.00601	CbGeAlD
Clodronate—Dehydration—Ritonavir—acquired immunodeficiency syndrome	0.00163	0.00289	CcSEcCtD
Clodronate—PTGS2—digestive system—acquired immunodeficiency syndrome	0.00163	0.00594	CbGeAlD
Clodronate—Pneumonia—Indinavir—acquired immunodeficiency syndrome	0.00163	0.00289	CcSEcCtD
Clodronate—SLC25A5—Metabolism—AGPS—acquired immunodeficiency syndrome	0.0016	0.00992	CbGpPWpGaD
Clodronate—PTGS2—Calcium signaling in the CD4+ TCR pathway—CD40LG—acquired immunodeficiency syndrome	0.0016	0.00992	CbGpPWpGaD
Clodronate—Renal failure—Indinavir—acquired immunodeficiency syndrome	0.00159	0.00282	CcSEcCtD
Clodronate—PTGS2—Calcium signaling in the CD4+ TCR pathway—CSF2—acquired immunodeficiency syndrome	0.00159	0.0098	CbGpPWpGaD
Clodronate—Blood creatinine increased—Saquinavir—acquired immunodeficiency syndrome	0.00158	0.00281	CcSEcCtD
Clodronate—SLC25A6—Metabolism—TAT—acquired immunodeficiency syndrome	0.00158	0.00977	CbGpPWpGaD
Clodronate—Dehydration—Saquinavir—acquired immunodeficiency syndrome	0.00157	0.00279	CcSEcCtD
Clodronate—Skin disorder—Amprenavir—acquired immunodeficiency syndrome	0.00157	0.00278	CcSEcCtD
Clodronate—PTGS2—Calcium signaling in the CD4+ TCR pathway—IL4—acquired immunodeficiency syndrome	0.00156	0.00965	CbGpPWpGaD
Clodronate—PTGS2—blood—acquired immunodeficiency syndrome	0.00155	0.00566	CbGeAlD
Clodronate—Pharyngitis—Zidovudine—acquired immunodeficiency syndrome	0.00155	0.00275	CcSEcCtD
Clodronate—Abdominal pain upper—Saquinavir—acquired immunodeficiency syndrome	0.00154	0.00274	CcSEcCtD
Clodronate—Urinary tract disorder—Zidovudine—acquired immunodeficiency syndrome	0.00154	0.00273	CcSEcCtD
Clodronate—Pneumonia—Efavirenz—acquired immunodeficiency syndrome	0.00154	0.00273	CcSEcCtD
Clodronate—Anorexia—Amprenavir—acquired immunodeficiency syndrome	0.00154	0.00273	CcSEcCtD
Clodronate—Connective tissue disorder—Zidovudine—acquired immunodeficiency syndrome	0.00153	0.00272	CcSEcCtD
Clodronate—SLC25A5—Disease—CCNT1—acquired immunodeficiency syndrome	0.00153	0.00947	CbGpPWpGaD
Clodronate—Urethral disorder—Zidovudine—acquired immunodeficiency syndrome	0.00153	0.00271	CcSEcCtD
Clodronate—Dysphagia—Ritonavir—acquired immunodeficiency syndrome	0.00152	0.00269	CcSEcCtD
Clodronate—SLC25A6—Disease—APOBEC3G—acquired immunodeficiency syndrome	0.00151	0.00933	CbGpPWpGaD
Clodronate—PTGS2—bone marrow—acquired immunodeficiency syndrome	0.0015	0.00547	CbGeAlD
Clodronate—Renal failure—Efavirenz—acquired immunodeficiency syndrome	0.0015	0.00266	CcSEcCtD
Clodronate—Dehydration—Lamivudine—acquired immunodeficiency syndrome	0.0015	0.00266	CcSEcCtD
Clodronate—Anaemia—Nevirapine—acquired immunodeficiency syndrome	0.0015	0.00265	CcSEcCtD
Clodronate—PTGS2—spinal cord—acquired immunodeficiency syndrome	0.0015	0.00545	CbGeAlD
Clodronate—Alanine aminotransferase increased—Saquinavir—acquired immunodeficiency syndrome	0.00149	0.00264	CcSEcCtD
Clodronate—Angioedema—Nevirapine—acquired immunodeficiency syndrome	0.00148	0.00262	CcSEcCtD
Clodronate—SLC25A4—HIV Infection—CCR5—acquired immunodeficiency syndrome	0.00147	0.0091	CbGpPWpGaD
Clodronate—Abdominal pain upper—Lamivudine—acquired immunodeficiency syndrome	0.00147	0.00261	CcSEcCtD
Clodronate—Pneumonia—Delavirdine—acquired immunodeficiency syndrome	0.00147	0.00261	CcSEcCtD
Clodronate—Infection—Didanosine—acquired immunodeficiency syndrome	0.00146	0.00259	CcSEcCtD
Clodronate—Dysphagia—Saquinavir—acquired immunodeficiency syndrome	0.00146	0.00259	CcSEcCtD
Clodronate—Anaemia—Nelfinavir—acquired immunodeficiency syndrome	0.00145	0.00257	CcSEcCtD
Clodronate—Anaemia—Stavudine—acquired immunodeficiency syndrome	0.00145	0.00256	CcSEcCtD
Clodronate—Pharyngitis—Indinavir—acquired immunodeficiency syndrome	0.00144	0.00256	CcSEcCtD
Clodronate—PTGS2—vagina—acquired immunodeficiency syndrome	0.00144	0.00524	CbGeAlD
Clodronate—Urinary tract disorder—Indinavir—acquired immunodeficiency syndrome	0.00143	0.00254	CcSEcCtD
Clodronate—Connective tissue disorder—Indinavir—acquired immunodeficiency syndrome	0.00143	0.00253	CcSEcCtD
Clodronate—Anaemia—Abacavir—acquired immunodeficiency syndrome	0.00142	0.00253	CcSEcCtD
Clodronate—Urethral disorder—Indinavir—acquired immunodeficiency syndrome	0.00142	0.00252	CcSEcCtD
Clodronate—SLC25A4—Host Interactions of HIV factors—CD4—acquired immunodeficiency syndrome	0.00142	0.00879	CbGpPWpGaD
Clodronate—Alanine aminotransferase increased—Lamivudine—acquired immunodeficiency syndrome	0.00142	0.00252	CcSEcCtD
Clodronate—SLC25A5—HIV Infection—CD4—acquired immunodeficiency syndrome	0.00141	0.00873	CbGpPWpGaD
Clodronate—Mediastinal disorder—Zidovudine—acquired immunodeficiency syndrome	0.00141	0.0025	CcSEcCtD
Clodronate—Decreased appetite—Amprenavir—acquired immunodeficiency syndrome	0.0014	0.00249	CcSEcCtD
Clodronate—Anorexia—Didanosine—acquired immunodeficiency syndrome	0.0014	0.00249	CcSEcCtD
Clodronate—Dysphagia—Lamivudine—acquired immunodeficiency syndrome	0.00139	0.00247	CcSEcCtD
Clodronate—Gastrointestinal disorder—Amprenavir—acquired immunodeficiency syndrome	0.00139	0.00247	CcSEcCtD
Clodronate—Unspecified disorder of skin and subcutaneous tissue—Nevirapine—acquired immunodeficiency syndrome	0.00137	0.00243	CcSEcCtD
Clodronate—PTGS2—lung—acquired immunodeficiency syndrome	0.00136	0.00496	CbGeAlD
Clodronate—Urinary tract disorder—Efavirenz—acquired immunodeficiency syndrome	0.00135	0.0024	CcSEcCtD
Clodronate—Connective tissue disorder—Efavirenz—acquired immunodeficiency syndrome	0.00135	0.00239	CcSEcCtD
Clodronate—Urethral disorder—Efavirenz—acquired immunodeficiency syndrome	0.00134	0.00239	CcSEcCtD
Clodronate—SLC25A6—Metabolism—AGPS—acquired immunodeficiency syndrome	0.00134	0.00831	CbGpPWpGaD
Clodronate—Renal failure—Ritonavir—acquired immunodeficiency syndrome	0.00133	0.00236	CcSEcCtD
Clodronate—Unspecified disorder of skin and subcutaneous tissue—Nelfinavir—acquired immunodeficiency syndrome	0.00133	0.00235	CcSEcCtD
Clodronate—Unspecified disorder of skin and subcutaneous tissue—Stavudine—acquired immunodeficiency syndrome	0.00132	0.00234	CcSEcCtD
Clodronate—Pneumonia—Saquinavir—acquired immunodeficiency syndrome	0.00131	0.00232	CcSEcCtD
Clodronate—Pharyngitis—Delavirdine—acquired immunodeficiency syndrome	0.0013	0.00231	CcSEcCtD
Clodronate—Unspecified disorder of skin and subcutaneous tissue—Abacavir—acquired immunodeficiency syndrome	0.0013	0.00231	CcSEcCtD
Clodronate—Dyspepsia—Didanosine—acquired immunodeficiency syndrome	0.00129	0.0023	CcSEcCtD
Clodronate—Skin disorder—Nevirapine—acquired immunodeficiency syndrome	0.00128	0.00228	CcSEcCtD
Clodronate—SLC25A6—Disease—CCNT1—acquired immunodeficiency syndrome	0.00128	0.00793	CbGpPWpGaD
Clodronate—Renal failure—Saquinavir—acquired immunodeficiency syndrome	0.00128	0.00227	CcSEcCtD
Clodronate—Decreased appetite—Didanosine—acquired immunodeficiency syndrome	0.00128	0.00227	CcSEcCtD
Clodronate—Abdominal pain—Amprenavir—acquired immunodeficiency syndrome	0.00127	0.00226	CcSEcCtD
Clodronate—PTGS2—nervous system—acquired immunodeficiency syndrome	0.00126	0.00459	CbGeAlD
Clodronate—Anorexia—Nevirapine—acquired immunodeficiency syndrome	0.00126	0.00223	CcSEcCtD
Clodronate—Anaemia—Zidovudine—acquired immunodeficiency syndrome	0.00126	0.00223	CcSEcCtD
Clodronate—Infection—Abacavir—acquired immunodeficiency syndrome	0.00125	0.00222	CcSEcCtD
Clodronate—Skin disorder—Nelfinavir—acquired immunodeficiency syndrome	0.00124	0.00221	CcSEcCtD
Clodronate—Angioedema—Zidovudine—acquired immunodeficiency syndrome	0.00124	0.0022	CcSEcCtD
Clodronate—Skin disorder—Stavudine—acquired immunodeficiency syndrome	0.00124	0.0022	CcSEcCtD
Clodronate—Mediastinal disorder—Efavirenz—acquired immunodeficiency syndrome	0.00124	0.00219	CcSEcCtD
Clodronate—SLC25A4—Metabolism—TAT—acquired immunodeficiency syndrome	0.00123	0.00763	CbGpPWpGaD
Clodronate—Skin disorder—Abacavir—acquired immunodeficiency syndrome	0.00122	0.00217	CcSEcCtD
Clodronate—Renal failure—Lamivudine—acquired immunodeficiency syndrome	0.00122	0.00216	CcSEcCtD
Clodronate—Anorexia—Nelfinavir—acquired immunodeficiency syndrome	0.00122	0.00216	CcSEcCtD
Clodronate—Anorexia—Stavudine—acquired immunodeficiency syndrome	0.00122	0.00216	CcSEcCtD
Clodronate—PTGS2—central nervous system—acquired immunodeficiency syndrome	0.00121	0.00442	CbGeAlD
Clodronate—Pharyngitis—Ritonavir—acquired immunodeficiency syndrome	0.0012	0.00214	CcSEcCtD
Clodronate—Urinary tract disorder—Ritonavir—acquired immunodeficiency syndrome	0.0012	0.00213	CcSEcCtD
Clodronate—Anorexia—Abacavir—acquired immunodeficiency syndrome	0.0012	0.00213	CcSEcCtD
Clodronate—Connective tissue disorder—Ritonavir—acquired immunodeficiency syndrome	0.00119	0.00212	CcSEcCtD
Clodronate—Urethral disorder—Ritonavir—acquired immunodeficiency syndrome	0.00119	0.00211	CcSEcCtD
Clodronate—SLC25A6—HIV Infection—CD4—acquired immunodeficiency syndrome	0.00118	0.00732	CbGpPWpGaD
Clodronate—SLC25A4—Disease—APOBEC3G—acquired immunodeficiency syndrome	0.00118	0.00728	CbGpPWpGaD
Clodronate—Anaemia—Indinavir—acquired immunodeficiency syndrome	0.00117	0.00207	CcSEcCtD
Clodronate—Abdominal pain—Didanosine—acquired immunodeficiency syndrome	0.00116	0.00206	CcSEcCtD
Clodronate—Pharyngitis—Saquinavir—acquired immunodeficiency syndrome	0.00116	0.00206	CcSEcCtD
Clodronate—Angioedema—Indinavir—acquired immunodeficiency syndrome	0.00115	0.00205	CcSEcCtD
Clodronate—Urinary tract disorder—Saquinavir—acquired immunodeficiency syndrome	0.00115	0.00205	CcSEcCtD
Clodronate—Unspecified disorder of skin and subcutaneous tissue—Zidovudine—acquired immunodeficiency syndrome	0.00115	0.00204	CcSEcCtD
Clodronate—Decreased appetite—Nevirapine—acquired immunodeficiency syndrome	0.00115	0.00204	CcSEcCtD
Clodronate—Connective tissue disorder—Saquinavir—acquired immunodeficiency syndrome	0.00115	0.00204	CcSEcCtD
Clodronate—Urethral disorder—Saquinavir—acquired immunodeficiency syndrome	0.00115	0.00203	CcSEcCtD
Clodronate—Dyspnoea—Nelfinavir—acquired immunodeficiency syndrome	0.00114	0.00202	CcSEcCtD
Clodronate—Gastrointestinal disorder—Nevirapine—acquired immunodeficiency syndrome	0.00114	0.00202	CcSEcCtD
Clodronate—Pruritus—Amprenavir—acquired immunodeficiency syndrome	0.00114	0.00202	CcSEcCtD
Clodronate—Dyspepsia—Nelfinavir—acquired immunodeficiency syndrome	0.00113	0.002	CcSEcCtD
Clodronate—Dyspepsia—Stavudine—acquired immunodeficiency syndrome	0.00112	0.00199	CcSEcCtD
Clodronate—Dyspnoea—Abacavir—acquired immunodeficiency syndrome	0.00112	0.00199	CcSEcCtD
Clodronate—Decreased appetite—Nelfinavir—acquired immunodeficiency syndrome	0.00111	0.00197	CcSEcCtD
Clodronate—Decreased appetite—Stavudine—acquired immunodeficiency syndrome	0.00111	0.00197	CcSEcCtD
Clodronate—Pharyngitis—Lamivudine—acquired immunodeficiency syndrome	0.00111	0.00196	CcSEcCtD
Clodronate—Gastrointestinal disorder—Nelfinavir—acquired immunodeficiency syndrome	0.0011	0.00196	CcSEcCtD
Clodronate—Anaemia—Efavirenz—acquired immunodeficiency syndrome	0.0011	0.00196	CcSEcCtD
Clodronate—Diarrhoea—Amprenavir—acquired immunodeficiency syndrome	0.0011	0.00196	CcSEcCtD
Clodronate—Gastrointestinal disorder—Stavudine—acquired immunodeficiency syndrome	0.0011	0.00195	CcSEcCtD
Clodronate—Connective tissue disorder—Lamivudine—acquired immunodeficiency syndrome	0.0011	0.00194	CcSEcCtD
Clodronate—Mediastinal disorder—Ritonavir—acquired immunodeficiency syndrome	0.00109	0.00194	CcSEcCtD
Clodronate—Decreased appetite—Abacavir—acquired immunodeficiency syndrome	0.00109	0.00194	CcSEcCtD
Clodronate—Angioedema—Efavirenz—acquired immunodeficiency syndrome	0.00109	0.00194	CcSEcCtD
Clodronate—Gastrointestinal disorder—Abacavir—acquired immunodeficiency syndrome	0.00109	0.00193	CcSEcCtD
Clodronate—Skin disorder—Zidovudine—acquired immunodeficiency syndrome	0.00108	0.00191	CcSEcCtD
Clodronate—Unspecified disorder of skin and subcutaneous tissue—Indinavir—acquired immunodeficiency syndrome	0.00107	0.0019	CcSEcCtD
Clodronate—Anorexia—Zidovudine—acquired immunodeficiency syndrome	0.00106	0.00188	CcSEcCtD
Clodronate—Anaemia—Delavirdine—acquired immunodeficiency syndrome	0.00106	0.00187	CcSEcCtD
Clodronate—Mediastinal disorder—Saquinavir—acquired immunodeficiency syndrome	0.00105	0.00187	CcSEcCtD
Clodronate—Urticaria—Nevirapine—acquired immunodeficiency syndrome	0.00105	0.00186	CcSEcCtD
Clodronate—SLC25A4—Metabolism—AGPS—acquired immunodeficiency syndrome	0.00105	0.00649	CbGpPWpGaD
Clodronate—Abdominal pain—Nevirapine—acquired immunodeficiency syndrome	0.00104	0.00185	CcSEcCtD
Clodronate—Angioedema—Delavirdine—acquired immunodeficiency syndrome	0.00104	0.00185	CcSEcCtD
Clodronate—Pruritus—Didanosine—acquired immunodeficiency syndrome	0.00104	0.00184	CcSEcCtD
Clodronate—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CD40LG—acquired immunodeficiency syndrome	0.00104	0.00641	CbGpPWpGaD
Clodronate—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CSF2—acquired immunodeficiency syndrome	0.00103	0.00634	CbGpPWpGaD
Clodronate—Vomiting—Amprenavir—acquired immunodeficiency syndrome	0.00103	0.00182	CcSEcCtD
Clodronate—Urticaria—Nelfinavir—acquired immunodeficiency syndrome	0.00102	0.0018	CcSEcCtD
Clodronate—Rash—Amprenavir—acquired immunodeficiency syndrome	0.00102	0.0018	CcSEcCtD
Clodronate—Dermatitis—Amprenavir—acquired immunodeficiency syndrome	0.00102	0.0018	CcSEcCtD
Clodronate—Urticaria—Stavudine—acquired immunodeficiency syndrome	0.00101	0.0018	CcSEcCtD
Clodronate—Abdominal pain—Nelfinavir—acquired immunodeficiency syndrome	0.00101	0.00179	CcSEcCtD
Clodronate—Unspecified disorder of skin and subcutaneous tissue—Efavirenz—acquired immunodeficiency syndrome	0.00101	0.00179	CcSEcCtD
Clodronate—Abdominal pain—Stavudine—acquired immunodeficiency syndrome	0.00101	0.00179	CcSEcCtD
Clodronate—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL4—acquired immunodeficiency syndrome	0.00101	0.00624	CbGpPWpGaD
Clodronate—Diarrhoea—Didanosine—acquired immunodeficiency syndrome	0.00101	0.00178	CcSEcCtD
Clodronate—Mediastinal disorder—Lamivudine—acquired immunodeficiency syndrome	0.001	0.00178	CcSEcCtD
Clodronate—Skin disorder—Indinavir—acquired immunodeficiency syndrome	0.001	0.00178	CcSEcCtD
Clodronate—SLC25A4—Disease—CCNT1—acquired immunodeficiency syndrome	0.001	0.00619	CbGpPWpGaD
Clodronate—Urticaria—Abacavir—acquired immunodeficiency syndrome	0.000999	0.00177	CcSEcCtD
Clodronate—Abdominal pain—Abacavir—acquired immunodeficiency syndrome	0.000994	0.00176	CcSEcCtD
Clodronate—Dyspnoea—Zidovudine—acquired immunodeficiency syndrome	0.000989	0.00175	CcSEcCtD
Clodronate—Anorexia—Indinavir—acquired immunodeficiency syndrome	0.000983	0.00174	CcSEcCtD
Clodronate—Anaemia—Ritonavir—acquired immunodeficiency syndrome	0.000976	0.00173	CcSEcCtD
Clodronate—Dyspepsia—Zidovudine—acquired immunodeficiency syndrome	0.000976	0.00173	CcSEcCtD
Clodronate—Decreased appetite—Zidovudine—acquired immunodeficiency syndrome	0.000964	0.00171	CcSEcCtD
Clodronate—PTGS2—brain—acquired immunodeficiency syndrome	0.000964	0.00351	CbGeAlD
Clodronate—Nausea—Amprenavir—acquired immunodeficiency syndrome	0.000958	0.0017	CcSEcCtD
Clodronate—Gastrointestinal disorder—Zidovudine—acquired immunodeficiency syndrome	0.000957	0.0017	CcSEcCtD
Clodronate—Skin disorder—Efavirenz—acquired immunodeficiency syndrome	0.000947	0.00168	CcSEcCtD
Clodronate—PTGS2—Calcium signaling in the CD4+ TCR pathway—IFNG—acquired immunodeficiency syndrome	0.000943	0.00583	CbGpPWpGaD
Clodronate—Anaemia—Saquinavir—acquired immunodeficiency syndrome	0.00094	0.00167	CcSEcCtD
Clodronate—Pruritus—Nevirapine—acquired immunodeficiency syndrome	0.000935	0.00166	CcSEcCtD
Clodronate—Vomiting—Didanosine—acquired immunodeficiency syndrome	0.000934	0.00166	CcSEcCtD
Clodronate—PTGS2—lymph node—acquired immunodeficiency syndrome	0.000931	0.00339	CbGeAlD
Clodronate—Anorexia—Efavirenz—acquired immunodeficiency syndrome	0.000929	0.00165	CcSEcCtD
Clodronate—Rash—Didanosine—acquired immunodeficiency syndrome	0.000927	0.00164	CcSEcCtD
Clodronate—Infection—Delavirdine—acquired immunodeficiency syndrome	0.000926	0.00164	CcSEcCtD
Clodronate—Dermatitis—Didanosine—acquired immunodeficiency syndrome	0.000926	0.00164	CcSEcCtD
Clodronate—SLC25A4—HIV Infection—CD4—acquired immunodeficiency syndrome	0.000924	0.00571	CbGpPWpGaD
Clodronate—Dyspnoea—Indinavir—acquired immunodeficiency syndrome	0.00092	0.00163	CcSEcCtD
Clodronate—Dyspepsia—Indinavir—acquired immunodeficiency syndrome	0.000908	0.00161	CcSEcCtD
Clodronate—Skin disorder—Delavirdine—acquired immunodeficiency syndrome	0.000906	0.00161	CcSEcCtD
Clodronate—Pruritus—Nelfinavir—acquired immunodeficiency syndrome	0.000906	0.00161	CcSEcCtD
Clodronate—Diarrhoea—Nevirapine—acquired immunodeficiency syndrome	0.000904	0.0016	CcSEcCtD
Clodronate—Pruritus—Stavudine—acquired immunodeficiency syndrome	0.000903	0.0016	CcSEcCtD
Clodronate—Decreased appetite—Indinavir—acquired immunodeficiency syndrome	0.000897	0.00159	CcSEcCtD
Clodronate—Anaemia—Lamivudine—acquired immunodeficiency syndrome	0.000897	0.00159	CcSEcCtD
Clodronate—Unspecified disorder of skin and subcutaneous tissue—Ritonavir—acquired immunodeficiency syndrome	0.000893	0.00158	CcSEcCtD
Clodronate—Gastrointestinal disorder—Indinavir—acquired immunodeficiency syndrome	0.00089	0.00158	CcSEcCtD
Clodronate—Pruritus—Abacavir—acquired immunodeficiency syndrome	0.000889	0.00158	CcSEcCtD
Clodronate—Anorexia—Delavirdine—acquired immunodeficiency syndrome	0.000889	0.00158	CcSEcCtD
Clodronate—Angioedema—Lamivudine—acquired immunodeficiency syndrome	0.000886	0.00157	CcSEcCtD
Clodronate—Urticaria—Zidovudine—acquired immunodeficiency syndrome	0.000881	0.00156	CcSEcCtD
Clodronate—Abdominal pain—Zidovudine—acquired immunodeficiency syndrome	0.000877	0.00156	CcSEcCtD
Clodronate—Diarrhoea—Nelfinavir—acquired immunodeficiency syndrome	0.000876	0.00155	CcSEcCtD
Clodronate—Diarrhoea—Stavudine—acquired immunodeficiency syndrome	0.000873	0.00155	CcSEcCtD
Clodronate—Nausea—Didanosine—acquired immunodeficiency syndrome	0.000873	0.00155	CcSEcCtD
Clodronate—Dyspnoea—Efavirenz—acquired immunodeficiency syndrome	0.000869	0.00154	CcSEcCtD
Clodronate—Diarrhoea—Abacavir—acquired immunodeficiency syndrome	0.00086	0.00153	CcSEcCtD
Clodronate—Unspecified disorder of skin and subcutaneous tissue—Saquinavir—acquired immunodeficiency syndrome	0.00086	0.00153	CcSEcCtD
Clodronate—Dyspepsia—Efavirenz—acquired immunodeficiency syndrome	0.000858	0.00152	CcSEcCtD
Clodronate—PTGS2—Overview of nanoparticle effects—TNF—acquired immunodeficiency syndrome	0.000856	0.00529	CbGpPWpGaD
Clodronate—Decreased appetite—Efavirenz—acquired immunodeficiency syndrome	0.000847	0.0015	CcSEcCtD
Clodronate—Gastrointestinal disorder—Efavirenz—acquired immunodeficiency syndrome	0.000841	0.00149	CcSEcCtD
Clodronate—Vomiting—Nevirapine—acquired immunodeficiency syndrome	0.00084	0.00149	CcSEcCtD
Clodronate—PTGS2—Calcium signaling in the CD4+ TCR pathway—IL2—acquired immunodeficiency syndrome	0.000838	0.00518	CbGpPWpGaD
Clodronate—Skin disorder—Ritonavir—acquired immunodeficiency syndrome	0.000838	0.00149	CcSEcCtD
Clodronate—Rash—Nevirapine—acquired immunodeficiency syndrome	0.000833	0.00148	CcSEcCtD
Clodronate—Dermatitis—Nevirapine—acquired immunodeficiency syndrome	0.000832	0.00148	CcSEcCtD
Clodronate—Dyspnoea—Delavirdine—acquired immunodeficiency syndrome	0.000831	0.00147	CcSEcCtD
Clodronate—Infection—Saquinavir—acquired immunodeficiency syndrome	0.000824	0.00146	CcSEcCtD
Clodronate—Anorexia—Ritonavir—acquired immunodeficiency syndrome	0.000822	0.00146	CcSEcCtD
Clodronate—Dyspepsia—Delavirdine—acquired immunodeficiency syndrome	0.000821	0.00146	CcSEcCtD
Clodronate—Unspecified disorder of skin and subcutaneous tissue—Lamivudine—acquired immunodeficiency syndrome	0.00082	0.00145	CcSEcCtD
Clodronate—Urticaria—Indinavir—acquired immunodeficiency syndrome	0.000819	0.00145	CcSEcCtD
Clodronate—Abdominal pain—Indinavir—acquired immunodeficiency syndrome	0.000815	0.00145	CcSEcCtD
Clodronate—Vomiting—Nelfinavir—acquired immunodeficiency syndrome	0.000814	0.00144	CcSEcCtD
Clodronate—Vomiting—Stavudine—acquired immunodeficiency syndrome	0.000811	0.00144	CcSEcCtD
Clodronate—Decreased appetite—Delavirdine—acquired immunodeficiency syndrome	0.000811	0.00144	CcSEcCtD
Clodronate—Rash—Nelfinavir—acquired immunodeficiency syndrome	0.000807	0.00143	CcSEcCtD
Clodronate—Dermatitis—Nelfinavir—acquired immunodeficiency syndrome	0.000806	0.00143	CcSEcCtD
Clodronate—Skin disorder—Saquinavir—acquired immunodeficiency syndrome	0.000806	0.00143	CcSEcCtD
Clodronate—Gastrointestinal disorder—Delavirdine—acquired immunodeficiency syndrome	0.000805	0.00143	CcSEcCtD
Clodronate—Rash—Stavudine—acquired immunodeficiency syndrome	0.000805	0.00143	CcSEcCtD
Clodronate—SLC25A5—Disease—CXCR4—acquired immunodeficiency syndrome	0.000804	0.00497	CbGpPWpGaD
Clodronate—Dermatitis—Stavudine—acquired immunodeficiency syndrome	0.000804	0.00143	CcSEcCtD
Clodronate—SLC25A4—SIDS Susceptibility Pathways—TNF—acquired immunodeficiency syndrome	0.000803	0.00497	CbGpPWpGaD
Clodronate—Vomiting—Abacavir—acquired immunodeficiency syndrome	0.000799	0.00142	CcSEcCtD
Clodronate—Rash—Abacavir—acquired immunodeficiency syndrome	0.000793	0.00141	CcSEcCtD
Clodronate—Dermatitis—Abacavir—acquired immunodeficiency syndrome	0.000792	0.0014	CcSEcCtD
Clodronate—Anorexia—Saquinavir—acquired immunodeficiency syndrome	0.000791	0.0014	CcSEcCtD
Clodronate—Infection—Lamivudine—acquired immunodeficiency syndrome	0.000787	0.0014	CcSEcCtD
Clodronate—Nausea—Nevirapine—acquired immunodeficiency syndrome	0.000785	0.00139	CcSEcCtD
Clodronate—Pruritus—Zidovudine—acquired immunodeficiency syndrome	0.000785	0.00139	CcSEcCtD
Clodronate—Urticaria—Efavirenz—acquired immunodeficiency syndrome	0.000774	0.00137	CcSEcCtD
Clodronate—Abdominal pain—Efavirenz—acquired immunodeficiency syndrome	0.00077	0.00137	CcSEcCtD
Clodronate—Skin disorder—Lamivudine—acquired immunodeficiency syndrome	0.000769	0.00136	CcSEcCtD
Clodronate—Dyspnoea—Ritonavir—acquired immunodeficiency syndrome	0.000769	0.00136	CcSEcCtD
Clodronate—Nausea—Nelfinavir—acquired immunodeficiency syndrome	0.00076	0.00135	CcSEcCtD
Clodronate—Dyspepsia—Ritonavir—acquired immunodeficiency syndrome	0.000759	0.00135	CcSEcCtD
Clodronate—Diarrhoea—Zidovudine—acquired immunodeficiency syndrome	0.000759	0.00135	CcSEcCtD
Clodronate—Nausea—Stavudine—acquired immunodeficiency syndrome	0.000758	0.00134	CcSEcCtD
Clodronate—Anorexia—Lamivudine—acquired immunodeficiency syndrome	0.000755	0.00134	CcSEcCtD
Clodronate—Decreased appetite—Ritonavir—acquired immunodeficiency syndrome	0.00075	0.00133	CcSEcCtD
Clodronate—Nausea—Abacavir—acquired immunodeficiency syndrome	0.000747	0.00132	CcSEcCtD
Clodronate—Gastrointestinal disorder—Ritonavir—acquired immunodeficiency syndrome	0.000744	0.00132	CcSEcCtD
Clodronate—Urticaria—Delavirdine—acquired immunodeficiency syndrome	0.000741	0.00131	CcSEcCtD
Clodronate—Dyspnoea—Saquinavir—acquired immunodeficiency syndrome	0.00074	0.00131	CcSEcCtD
Clodronate—Abdominal pain—Delavirdine—acquired immunodeficiency syndrome	0.000737	0.00131	CcSEcCtD
Clodronate—PTGS2—Spinal Cord Injury—CCR2—acquired immunodeficiency syndrome	0.000732	0.00453	CbGpPWpGaD
Clodronate—Dyspepsia—Saquinavir—acquired immunodeficiency syndrome	0.000731	0.0013	CcSEcCtD
Clodronate—Pruritus—Indinavir—acquired immunodeficiency syndrome	0.00073	0.00129	CcSEcCtD
Clodronate—Decreased appetite—Saquinavir—acquired immunodeficiency syndrome	0.000721	0.00128	CcSEcCtD
Clodronate—Gastrointestinal disorder—Saquinavir—acquired immunodeficiency syndrome	0.000716	0.00127	CcSEcCtD
Clodronate—Dyspnoea—Lamivudine—acquired immunodeficiency syndrome	0.000706	0.00125	CcSEcCtD
Clodronate—Diarrhoea—Indinavir—acquired immunodeficiency syndrome	0.000706	0.00125	CcSEcCtD
Clodronate—Vomiting—Zidovudine—acquired immunodeficiency syndrome	0.000705	0.00125	CcSEcCtD
Clodronate—Rash—Zidovudine—acquired immunodeficiency syndrome	0.000699	0.00124	CcSEcCtD
Clodronate—Dermatitis—Zidovudine—acquired immunodeficiency syndrome	0.000699	0.00124	CcSEcCtD
Clodronate—Dyspepsia—Lamivudine—acquired immunodeficiency syndrome	0.000697	0.00124	CcSEcCtD
Clodronate—PTGS2—Overview of nanoparticle effects—IL6—acquired immunodeficiency syndrome	0.000691	0.00427	CbGpPWpGaD
Clodronate—Pruritus—Efavirenz—acquired immunodeficiency syndrome	0.000689	0.00122	CcSEcCtD
Clodronate—Decreased appetite—Lamivudine—acquired immunodeficiency syndrome	0.000688	0.00122	CcSEcCtD
Clodronate—Urticaria—Ritonavir—acquired immunodeficiency syndrome	0.000685	0.00122	CcSEcCtD
Clodronate—Gastrointestinal disorder—Lamivudine—acquired immunodeficiency syndrome	0.000684	0.00121	CcSEcCtD
Clodronate—Abdominal pain—Ritonavir—acquired immunodeficiency syndrome	0.000682	0.00121	CcSEcCtD
Clodronate—SLC25A6—Disease—CXCR4—acquired immunodeficiency syndrome	0.000674	0.00417	CbGpPWpGaD
Clodronate—Diarrhoea—Efavirenz—acquired immunodeficiency syndrome	0.000667	0.00118	CcSEcCtD
Clodronate—Pruritus—Delavirdine—acquired immunodeficiency syndrome	0.00066	0.00117	CcSEcCtD
Clodronate—Urticaria—Saquinavir—acquired immunodeficiency syndrome	0.000659	0.00117	CcSEcCtD
Clodronate—Nausea—Zidovudine—acquired immunodeficiency syndrome	0.000659	0.00117	CcSEcCtD
Clodronate—Abdominal pain—Saquinavir—acquired immunodeficiency syndrome	0.000656	0.00116	CcSEcCtD
Clodronate—Vomiting—Indinavir—acquired immunodeficiency syndrome	0.000656	0.00116	CcSEcCtD
Clodronate—Rash—Indinavir—acquired immunodeficiency syndrome	0.00065	0.00115	CcSEcCtD
Clodronate—Dermatitis—Indinavir—acquired immunodeficiency syndrome	0.00065	0.00115	CcSEcCtD
Clodronate—SLC25A4—SIDS Susceptibility Pathways—IL6—acquired immunodeficiency syndrome	0.000648	0.00401	CbGpPWpGaD
Clodronate—Diarrhoea—Delavirdine—acquired immunodeficiency syndrome	0.000638	0.00113	CcSEcCtD
Clodronate—Urticaria—Lamivudine—acquired immunodeficiency syndrome	0.000629	0.00112	CcSEcCtD
Clodronate—Abdominal pain—Lamivudine—acquired immunodeficiency syndrome	0.000626	0.00111	CcSEcCtD
Clodronate—Vomiting—Efavirenz—acquired immunodeficiency syndrome	0.00062	0.0011	CcSEcCtD
Clodronate—Rash—Efavirenz—acquired immunodeficiency syndrome	0.000614	0.00109	CcSEcCtD
Clodronate—Dermatitis—Efavirenz—acquired immunodeficiency syndrome	0.000614	0.00109	CcSEcCtD
Clodronate—Nausea—Indinavir—acquired immunodeficiency syndrome	0.000613	0.00109	CcSEcCtD
Clodronate—Pruritus—Ritonavir—acquired immunodeficiency syndrome	0.00061	0.00108	CcSEcCtD
Clodronate—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IFNG—acquired immunodeficiency syndrome	0.00061	0.00377	CbGpPWpGaD
Clodronate—Vomiting—Delavirdine—acquired immunodeficiency syndrome	0.000593	0.00105	CcSEcCtD
Clodronate—Diarrhoea—Ritonavir—acquired immunodeficiency syndrome	0.00059	0.00105	CcSEcCtD
Clodronate—Rash—Delavirdine—acquired immunodeficiency syndrome	0.000588	0.00104	CcSEcCtD
Clodronate—Dermatitis—Delavirdine—acquired immunodeficiency syndrome	0.000587	0.00104	CcSEcCtD
Clodronate—Pruritus—Saquinavir—acquired immunodeficiency syndrome	0.000587	0.00104	CcSEcCtD
Clodronate—Nausea—Efavirenz—acquired immunodeficiency syndrome	0.000579	0.00103	CcSEcCtD
Clodronate—Diarrhoea—Saquinavir—acquired immunodeficiency syndrome	0.000568	0.00101	CcSEcCtD
Clodronate—Pruritus—Lamivudine—acquired immunodeficiency syndrome	0.00056	0.000994	CcSEcCtD
Clodronate—Nausea—Delavirdine—acquired immunodeficiency syndrome	0.000554	0.000982	CcSEcCtD
Clodronate—SLC25A5—Disease—CCR5—acquired immunodeficiency syndrome	0.000551	0.00341	CbGpPWpGaD
Clodronate—Vomiting—Ritonavir—acquired immunodeficiency syndrome	0.000548	0.000973	CcSEcCtD
Clodronate—Rash—Ritonavir—acquired immunodeficiency syndrome	0.000544	0.000964	CcSEcCtD
Clodronate—Dermatitis—Ritonavir—acquired immunodeficiency syndrome	0.000543	0.000964	CcSEcCtD
Clodronate—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL2—acquired immunodeficiency syndrome	0.000542	0.00335	CbGpPWpGaD
Clodronate—Diarrhoea—Lamivudine—acquired immunodeficiency syndrome	0.000542	0.000961	CcSEcCtD
Clodronate—Vomiting—Saquinavir—acquired immunodeficiency syndrome	0.000528	0.000936	CcSEcCtD
Clodronate—SLC25A4—Disease—CXCR4—acquired immunodeficiency syndrome	0.000526	0.00325	CbGpPWpGaD
Clodronate—Rash—Saquinavir—acquired immunodeficiency syndrome	0.000523	0.000928	CcSEcCtD
Clodronate—Dermatitis—Saquinavir—acquired immunodeficiency syndrome	0.000523	0.000927	CcSEcCtD
Clodronate—Nausea—Ritonavir—acquired immunodeficiency syndrome	0.000512	0.000909	CcSEcCtD
Clodronate—PTGS2—Spinal Cord Injury—IL4—acquired immunodeficiency syndrome	0.000507	0.00314	CbGpPWpGaD
Clodronate—Vomiting—Lamivudine—acquired immunodeficiency syndrome	0.000503	0.000893	CcSEcCtD
Clodronate—Rash—Lamivudine—acquired immunodeficiency syndrome	0.000499	0.000886	CcSEcCtD
Clodronate—Dermatitis—Lamivudine—acquired immunodeficiency syndrome	0.000499	0.000885	CcSEcCtD
Clodronate—Nausea—Saquinavir—acquired immunodeficiency syndrome	0.000493	0.000874	CcSEcCtD
Clodronate—Nausea—Lamivudine—acquired immunodeficiency syndrome	0.00047	0.000834	CcSEcCtD
Clodronate—PTGS2—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	0.000466	0.00288	CbGpPWpGaD
Clodronate—SLC25A6—Disease—CCR5—acquired immunodeficiency syndrome	0.000462	0.00286	CbGpPWpGaD
Clodronate—PTGS2—Selenium Micronutrient Network—ALB—acquired immunodeficiency syndrome	0.000425	0.00263	CbGpPWpGaD
Clodronate—PTGS2—Aryl Hydrocarbon Receptor—TNF—acquired immunodeficiency syndrome	0.000422	0.00261	CbGpPWpGaD
Clodronate—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—acquired immunodeficiency syndrome	0.000395	0.00244	CbGpPWpGaD
Clodronate—PTGS2—C-MYB transcription factor network—CD4—acquired immunodeficiency syndrome	0.000389	0.0024	CbGpPWpGaD
Clodronate—PTGS2—Selenium Micronutrient Network—IFNG—acquired immunodeficiency syndrome	0.000388	0.0024	CbGpPWpGaD
Clodronate—SLC25A4—Disease—CCR5—acquired immunodeficiency syndrome	0.00036	0.00223	CbGpPWpGaD
Clodronate—SLC25A5—Disease—CD4—acquired immunodeficiency syndrome	0.000346	0.00214	CbGpPWpGaD
Clodronate—SLC25A5—Metabolism—ALB—acquired immunodeficiency syndrome	0.000329	0.00203	CbGpPWpGaD
Clodronate—PTGS2—Spinal Cord Injury—IFNG—acquired immunodeficiency syndrome	0.000307	0.0019	CbGpPWpGaD
Clodronate—SLC25A6—Disease—CD4—acquired immunodeficiency syndrome	0.00029	0.00179	CbGpPWpGaD
Clodronate—SLC25A6—Metabolism—ALB—acquired immunodeficiency syndrome	0.000276	0.0017	CbGpPWpGaD
Clodronate—PTGS2—Spinal Cord Injury—IL2—acquired immunodeficiency syndrome	0.000273	0.00169	CbGpPWpGaD
Clodronate—PTGS2—Selenium Micronutrient Network—TNF—acquired immunodeficiency syndrome	0.000251	0.00155	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—TAT—acquired immunodeficiency syndrome	0.000244	0.00151	CbGpPWpGaD
Clodronate—PTGS2—Disease—APOBEC3G—acquired immunodeficiency syndrome	0.000233	0.00144	CbGpPWpGaD
Clodronate—SLC25A4—Disease—CD4—acquired immunodeficiency syndrome	0.000226	0.0014	CbGpPWpGaD
Clodronate—SLC25A4—Metabolism—ALB—acquired immunodeficiency syndrome	0.000215	0.00133	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—AGPS—acquired immunodeficiency syndrome	0.000207	0.00128	CbGpPWpGaD
Clodronate—PTGS2—Selenium Micronutrient Network—IL6—acquired immunodeficiency syndrome	0.000203	0.00125	CbGpPWpGaD
Clodronate—PTGS2—Spinal Cord Injury—TNF—acquired immunodeficiency syndrome	0.000199	0.00123	CbGpPWpGaD
Clodronate—PTGS2—Disease—CCNT1—acquired immunodeficiency syndrome	0.000198	0.00122	CbGpPWpGaD
Clodronate—SLC25A5—Disease—IL6—acquired immunodeficiency syndrome	0.000187	0.00116	CbGpPWpGaD
Clodronate—PTGS2—Spinal Cord Injury—IL6—acquired immunodeficiency syndrome	0.00016	0.000991	CbGpPWpGaD
Clodronate—SLC25A6—Disease—IL6—acquired immunodeficiency syndrome	0.000157	0.00097	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—acquired immunodeficiency syndrome	0.000135	0.000835	CbGpPWpGaD
Clodronate—SLC25A4—Disease—IL6—acquired immunodeficiency syndrome	0.000122	0.000757	CbGpPWpGaD
Clodronate—PTGS2—Disease—CXCR4—acquired immunodeficiency syndrome	0.000104	0.000643	CbGpPWpGaD
Clodronate—PTGS2—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	9.55e-05	0.000591	CbGpPWpGaD
Clodronate—PTGS2—Disease—CCR5—acquired immunodeficiency syndrome	7.13e-05	0.000441	CbGpPWpGaD
Clodronate—PTGS2—Disease—CD4—acquired immunodeficiency syndrome	4.48e-05	0.000277	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—ALB—acquired immunodeficiency syndrome	4.25e-05	0.000263	CbGpPWpGaD
Clodronate—PTGS2—Disease—IL6—acquired immunodeficiency syndrome	2.42e-05	0.00015	CbGpPWpGaD
